New CEO leadership team at IFPMA

12 July 2023

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the global sector trade body, today announced a new line up for its chief executive (CEO) leadership team for the coming two years.

The CEOs who will provide strategic guidance to the organization include Albert Bourla, chairman and chief executive of Pfizer (NYSE: PFE), who has been announced as the new president of the IFPMA and will serve as the chairman of the IFPMA CEO Steering Committee. He will be joined by vice president Thomas Schinecker, CEO of Roche (ROG: SIX), who will serve alongside existing VP, Sunao Manabe, executive chairperson and CEO of Daiichi Sankyo (TYO: 4568).

Albert Bourla, currently vice president of the IFPMA, assumes the role from Jean-Christophe Tellier, CEO and chairman of UCB (Euronext: UCB), who has been in post since January 2021.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK